Literature DB >> 8543371

Inhibition of neutrophil chemotaxis by protease inhibitors. Differential effect of inhibitors of serine and thiol proteases.

J B Barna1, R R Kew.   

Abstract

Previous studies have demonstrated that neutrophils possess an active serine protease(s) which may be involved in the process of chemotaxis but the precise identity of this enzyme(s) remains to be determined. In this study fourteen different protease inhibitors were tested over a wide concentration range for their ability to inhibit unstimulated neutrophil movement and chemotaxis to C5a, fMLP and IL-8. Pretreatment of neutrophils with aspartyl or metallo-protease inhibitors had no effect on either chemotaxis or random cell movement. The thiol protease inhibitors E-64 and cystatin, as well as the thiol/serine inhibitors antipain and leupeptin, diminished only C5a-induced chemotaxis. Pretreatment of neutrophils with the serine protease inhibitors PMSF or 3,4-DCI significantly reduced chemotaxis to C5a, fMLP and IL-8. The inhibitor of trypsin-like serine proteases, TLCK, and the neutrophil elastase inhibitor MeO-Suc-AAPV-CMK had no inhibitory effect on cell movement. However, two different inhibitors of chymotrypsin-like serine proteases, TPCK and chymostatin, significantly inhibited movement to any chemoattractant. These results suggest that an active chymotrypsin-like serine protease is essential for neutrophils to respond to chemotactic stimuli.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8543371     DOI: 10.1007/bf01539136

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  41 in total

Review 1.  Chemoattractant stimulation of polymorphonuclear leucocyte locomotion.

Authors:  L Cassimeris; S H Zigmond
Journal:  Semin Cell Biol       Date:  1990-04

2.  Proteolysis of C3 on U937 cell plasma membranes. Purification of cathepsin G.

Authors:  C M Maison; C L Villiers; M G Colomb
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

3.  Effects of alpha 1-proteinase inhibitor on chemotaxis and chemokinesis of polymorphonuclear leukocytes: its possible role in regulating polymorphonuclear leukocyte recruitment in human subjects.

Authors:  K Aoshiba; A Nagai; Y Ishihara; J Kagawa; T Takizawa
Journal:  J Lab Clin Med       Date:  1993-09

4.  Inhibition of 125I-chemotactic peptide uptake by protease inhibitors.

Authors:  J Niedel; R Frothingham; P Cuatrecasas
Journal:  Biochem Biophys Res Commun       Date:  1980-05-30       Impact factor: 3.575

5.  Generation of biologically active C-reactive protein peptides by a neutral protease on the membrane of phorbol myristate acetate-stimulated neutrophils.

Authors:  E G Shephard; S M Beer; R Anderson; A F Strachan; A E Nel; F C de Beer
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

6.  Alpha-1-antichymotrypsin inhibits the NADPH oxidase-enzyme complex in phorbol ester-stimulated neutrophil membranes.

Authors:  L Kilpatrick; L McCawley; V Nachiappan; W Greer; S Majumdar; H M Korchak; S D Douglas
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

7.  Neutrophil chemotactic activity is modulated by human cystatin C, an inhibitor of cysteine proteases.

Authors:  J Leung-Tack; C Tavera; J Martinez; A Colle
Journal:  Inflammation       Date:  1990-06       Impact factor: 4.092

8.  Effect of alpha-1-proteinase inhibitor on neutrophil chemotaxis.

Authors:  R A Stockley; J Shaw; S C Afford; H M Morrison; D Burnett
Journal:  Am J Respir Cell Mol Biol       Date:  1990-02       Impact factor: 6.914

9.  Esterase dependence of human neutrophil functions: lysozyme secretion, spontaneous migration, and continuity of the respiratory burst.

Authors:  R D Nelson; M J Herron; J M Gracyk; R L Simmons
Journal:  J Infect Dis       Date:  1981-01       Impact factor: 5.226

10.  Esterases of the polymorphonuclear leukocyte capable of hydrolyzing acetyl DL-phenyl-alanine beta-naphthyl ester. Relationship to the activatable esterase of chemotaxis.

Authors:  E L Becker; P A Ward
Journal:  J Exp Med       Date:  1969-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.